List of Excipients in Branded Drug ULTRAVATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	ULTRAVATE	halobetasol propionate	10631-122	BUTYLPARABEN
Sun Pharmaceutical Industries Inc	ULTRAVATE	halobetasol propionate	10631-122	CARBOMER HOMOPOLYMER TYPE C
Sun Pharmaceutical Industries Inc	ULTRAVATE	halobetasol propionate	10631-122	CETETH-20
Sun Pharmaceutical Industries Inc	ULTRAVATE	halobetasol propionate	10631-122	CETYL ALCOHOL

Ultravate Excipient Strategy and Commercial Opportunities for Halobetasol Propionate

Last updated: August 1, 2026

Ultravate is a topical halobetasol propionate product containing a super-high-potency corticosteroid. Its commercial opportunity is concentrated in vehicle differentiation, generic substitution, adherence, dermatology-focused distribution, and lifecycle products rather than in new systemic indications. Excipient selection must balance skin penetration against local tolerability, preservative burden, cosmetic acceptability, and the FDA’s limits on duration and quantity of use.

What is Ultravate and how is it regulated?

Ultravate contains halobetasol propionate 0.05%, a topical corticosteroid indicated for short-term treatment of corticosteroid-responsive dermatoses, including plaque psoriasis and atopic dermatitis in certain formulations. The product is intended for use in adults and, depending on the formulation and label, pediatric patients aged 12 years and older. Treatment is generally limited to two consecutive weeks, and total dosage should not exceed 50 grams per week because of the risk of hypothalamic-pituitary-adrenal-axis suppression and other corticosteroid-related adverse effects. [1]

What dosage forms does Ultravate have?

The Ultravate product family has included:

Product	Active ingredient	Strength	Dosage form	Primary commercial attribute
Ultravate cream	Halobetasol propionate	0.05%	Cream	Conventional emulsion vehicle
Ultravate ointment	Halobetasol propionate	0.05%	Ointment	Occlusive, high-emollience vehicle
Ultravate lotion	Halobetasol propionate	0.05%	Lotion	Lower-grease, spreadable vehicle

The FDA labeling for Ultravate lotion identifies excipients including carbomer, cetostearyl alcohol, diethyl sebacate, edetate disodium, glycerin, glyceryl stearate, isopropyl alcohol, polysorbate 60, purified water, sodium hydroxide, and stearyl alcohol. [2]

The cream and ointment formulations use different excipient systems. The cream contains an emulsion base with ingredients such as cetostearyl alcohol, chlorocresol, glyceryl stearate, isopropyl myristate, liquid paraffin, polysorbate 60, sodium citrate, stearic acid, and purified water. The ointment uses a substantially more occlusive hydrocarbon-based system. [3]

What excipient strategy does Ultravate use?

Ultravate’s formulation strategy is based on delivering a highly potent, lipophilic corticosteroid through a topical vehicle that supports deposition in the epidermis and upper dermis while maintaining acceptable spreadability.

How do the excipients function?

Excipient category	Representative Ultravate ingredients	Formulation role
Emollients and fatty alcohols	Cetostearyl alcohol, stearyl alcohol	Improve consistency, skin feel, emollience, and emulsion stability
Emulsifiers	Glyceryl stearate, polysorbate 60	Stabilize oil-in-water emulsion systems
Humectants	Glycerin	Supports hydration and reduces dry-skin feel
Solvents and penetration-supporting agents	Isopropyl alcohol, diethyl sebacate, isopropyl myristate	Improve wetting, spreadability, drug solubilization, and skin partitioning
Rheology modifiers	Carbomer	Increases viscosity and supports lotion structure
Chelating agents	Edetate disodium	Binds trace metals and improves formulation stability
pH adjusters and buffers	Sodium hydroxide, sodium citrate	Establish and maintain suitable pH
Preservatives	Chlorocresol in the cream formulation	Controls microbial growth in the aqueous product
Occlusive base	Mineral oil, petrolatum-type components	Reduces transepidermal water loss and increases hydration

The vehicle determines more than appearance. It influences drug release, partitioning into stratum corneum lipids, evaporation after application, residence time, washability, patient preference, and the risk of overuse.

Which excipient opportunities are most commercially attractive?

The strongest opportunities are non-infringing or independently protectable vehicles that improve patient acceptability without materially increasing systemic corticosteroid exposure.

1. Low-grease lotion and cream vehicles

Many patients avoid ointments because of greasiness, transfer to clothing, and poor suitability for hairy or large body areas. A lotion or light cream can improve use on the trunk, extremities, and scalp-adjacent skin.

Commercial differentiation can focus on:

• Rapid rub-in
• Reduced tack and residue
• Lower transfer to clothing
• Easy application over large areas
• Stable viscosity across temperature ranges
• Compatibility with tubes, pumps, or airless containers

The main development constraint is that lower-viscosity systems can increase solvent evaporation and alter drug crystallization. Halobetasol propionate must remain uniformly distributed during storage and application.

2. Foam and mousse-like delivery systems

Foam technology has commercial value in dermatology because it spreads rapidly, dries quickly, and can be used on hair-bearing areas. The category has been established for other potent corticosteroids, including clobetasol propionate and betamethasone formulations.

A halobetasol foam could target:

• Scalp and intertriginous areas
• Patients who reject ointments
• Rapid application over plaques
• Premium dermatology dispensing
• Improved cosmetic acceptability

The principal technical risks are flammability for hydrocarbon-propelled systems, container compatibility, dose uniformity, propellant selection, and preservation after dispensing. A foam would also require careful clinical and regulatory positioning because a more cosmetically acceptable vehicle could increase frequency or area of use.

3. Spray and solution systems

Sprays and solutions may offer a differentiated delivery format for scalp psoriasis and difficult-to-reach areas. Alcohol-containing systems can improve drying and reduce greasy residue, but they may sting on fissured or inflamed skin.

Potential excipient approaches include:

• Ethanol or isopropanol for rapid evaporation
• Propylene glycol or diethyl sebacate as co-solvents
• Low-residue polymeric film formers
• Metered-dose pumps for application control
• Non-aerosol spray packaging to reduce flammability concerns

The commercial advantage is convenience. The development challenge is maintaining uniform dosing while avoiding excessive irritation.

4. Barrier-supportive vehicles

Ultravate treats inflammation but does not replace barrier-repair therapy. A formulation that combines halobetasol propionate with barrier-supportive excipients could improve patient experience, provided the excipients do not increase potency beyond the intended exposure profile.

Candidate excipient classes include:

• Ceramides
• Cholesterol
• Fatty acids
• Squalane
• Colloidal oatmeal
• Panthenol
• Dimethicone
• Glycerin
• Urea at carefully selected concentrations

A barrier-supportive product could be positioned for patients with very dry plaques or dermatitis. The formulation must avoid creating an occlusive environment that materially increases corticosteroid absorption, especially in folds or under dressings.

What formulations are protected by Ultravate-related patents?

The commercial protection around topical halobetasol products can arise from several sources:

1. The active ingredient and its original pharmaceutical use.
2. Specific cream, ointment, lotion, foam, or spray vehicles.
3. Particle-size or crystal-form controls.
4. Drug-release profiles.
5. Packaging and dispensing systems.
6. Treatment regimens, including intermittent use or defined body sites.
7. Combination products containing halobetasol and another active ingredient.

For a generic or follow-on developer, the key issue is whether the proposed product is an equivalent formulation under the applicable FDA pathway or a distinct product requiring additional clinical support.

What is the Orange Book status of Ultravate?

Ultravate is associated with an FDA-approved new drug application for halobetasol propionate topical products. Orange Book analysis should distinguish:

• Patents listed for the specific reference product;
• Patents listed for a dosage form or formulation;
• Regulatory exclusivity that has expired;
• Patent claims that may no longer block approval because of expiration or delisting;
• Separate patents covering later products or other halobetasol vehicles.

For an abbreviated new drug application, a manufacturer must evaluate the reference product’s current Orange Book listing and submit the appropriate certification, including Paragraph IV where applicable. FDA approval does not itself resolve patent enforceability. [4]

Because topical products can have multiple reference standards by dosage form, a cream generic cannot automatically be substituted for a lotion or ointment product. The applicant must establish the applicable product-specific equivalence requirements.

When does Ultravate lose exclusivity?

Ultravate’s primary regulatory exclusivity period has expired. The commercial market is therefore governed mainly by patent status, product-specific approval requirements, manufacturing capability, and prescriber preference.

A precise launch analysis requires review of the current Orange Book entry, patent certifications, litigation outcomes, and any settlement restrictions. The relevant commercial conclusion is that the opportunity is principally a generic and differentiated-topical opportunity, not a new chemical entity exclusivity opportunity.

What generic entry risks exist?

Generic entry risk is high for conventional halobetasol cream and ointment products because:

• The active ingredient is well established.
• The products are topical and locally acting.
• Multiple generic manufacturers have experience with corticosteroid semisolids.
• The formulations use widely available excipients.
• The market has established reference standards.

Entry risk is lower for technically differentiated products such as:

• Foam
• Metered spray
• Low-residue lotion
• Airless-pump emulsion
• Barrier-supportive combination vehicle
• Formulation with a distinct release or application profile

These products may require greater development investment, but they can support higher pricing and stronger differentiation.

How strong is the Ultravate patent estate?

The strength of a halobetasol product estate depends less on the basic molecule and more on the enforceability of formulation and method claims.

Stronger claim types

The most commercially useful claims generally cover:

• A narrow excipient concentration range;
• A defined particle-size distribution;
• A specific solubilized or dispersed state;
• A formulation with improved stability;
• A delivery system that produces a measured pharmacokinetic or dermatologic benefit;
• A combination with a second active ingredient;
• A defined treatment regimen supported by clinical data.

Weaker claim types

Claims are more vulnerable when they cover:

• Broad lists of conventional excipients;
• Routine cream or ointment compositions;
• Overlapping concentration ranges;
• Functional language without strong comparative data;
• Vehicles that can be designed around with common formulation changes.

A product relying on standard cetostearyl alcohol, glyceryl stearate, petrolatum, glycerin, and surfactant systems is generally easier to design around than a product supported by a specific microstructure, drug-release profile, or validated performance advantage.

Which companies are challenging or competing with Ultravate?

Competition comes from three groups.

Generic halobetasol manufacturers

Generic manufacturers compete through:

• Lower acquisition cost;
• Contract pharmacy access;
• Formulary placement;
• Authorized generic arrangements;
• Standardized cream, ointment, and lotion products.

The competitive threat is strongest in high-volume conventional dosage forms.

Branded topical corticosteroid companies

Branded competitors include manufacturers of clobetasol propionate, betamethasone dipropionate, fluocinonide, desoximetasone, and other high-potency corticosteroids. Their products compete on vehicle, site of application, prescriber familiarity, and payer coverage.

Nonsteroidal dermatology products

Nonsteroidal alternatives, including topical calcineurin inhibitors, phosphodiesterase-4 inhibitors, Janus kinase inhibitors, and aryl hydrocarbon receptor agonists, compete for patients who require repeated treatment or have concerns about corticosteroid exposure.

Ultravate’s strongest position remains short-course treatment of localized flares where high potency and rapid anti-inflammatory activity are valued.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve technology than the halobetasol molecule itself.

Potential deal structures include:

Asset	Potential partner	Commercial rationale
Foam or aerosol platform	Dermatology specialty company	Adds a differentiated vehicle to an established active
Airless-pump technology	Packaging or topical-drug developer	Improves dosing and reduces contamination
Barrier-repair excipient system	Skin-care or prescription dermatology company	Supports premium positioning
Controlled-release polymer	Drug-delivery company	Creates formulation patentability
Regional generic rights	Local pharmaceutical manufacturer	Expands geographic coverage
Co-development of combination product	Specialty dermatology company	Builds a larger treatment platform

The licensing value depends on freedom to operate, clinical differentiation, manufacturing scale, and payer willingness to reimburse a premium over generic halobetasol.

What manufacturing and intellectual-property barriers matter?

Halobetasol semisolids are not difficult to manufacture at a basic level, but quality and equivalence can be difficult to control.

Important manufacturing variables include:

• Drug dispersion and deagglomeration;
• Control of polymorphic or crystalline material;
• Uniformity across filling batches;
• Emulsion droplet size;
• Viscosity and yield stress;
• Preservative effectiveness;
• Tube or pump compatibility;
• Stability under heat and freeze-thaw conditions;
• Microbial limits;
• In-use stability.

Topical products can generate regulatory complexity because in vitro release testing, dermatopharmacokinetic evidence, comparative clinical endpoint data, and product-specific bioequivalence expectations may all affect approval strategy. FDA guidance has increasingly emphasized performance testing for topical semisolid products. [5]

What FDA regulatory pathway applies to a new Ultravate product?

A conventional generic halobetasol product will usually proceed through an ANDA if it references an appropriate listed drug and satisfies the applicable equivalence requirements.

A materially different product may require:

• An ANDA with a different inactive-ingredient justification;
• A suitability petition in limited circumstances;
• A 505(b)(2) application;
• Comparative clinical endpoint studies;
• Human pharmacokinetic or dermatopharmacodynamic evidence;
• Additional local tolerability or irritation testing.

The regulatory pathway affects both development cost and patent exposure. A 505(b)(2) product may support greater formulation differentiation but can face listed-patent certifications and more extensive clinical requirements.

How does Ultravate compare with competing topical corticosteroids?

Product class	Relative potency	Vehicle opportunity	Commercial risk
Halobetasol propionate	Super-high	Lotion, foam, spray, barrier-supportive cream	Short treatment duration limits repeat use
Clobetasol propionate	Super-high	Foam, shampoo, solution, emulsion	Strong generic and branded competition
Betamethasone dipropionate	High to super-high, depending on vehicle	Lotion, ointment, cream, augmented vehicles	Broad historical use and crowded market
Fluocinonide	High	Solution, gel, cream, ointment	Established low-cost generic competition
Nonsteroidal agents	Not corticosteroid-based	Cream, ointment, foam, topical solution	Higher acquisition cost but broader chronic-use positioning

Ultravate can compete effectively when a prescriber prioritizes high potency and short-course control. It is less advantaged when long-term maintenance, sensitive-site use, pediatric use, or steroid avoidance drives treatment selection.

What is the revenue exposure and commercial opportunity?

Revenue exposure is concentrated in the following areas:

1. Price erosion in conventional cream and ointment products.
2. Substitution by lower-cost generic halobetasol.
3. Declining use in patients requiring chronic maintenance therapy.
4. Competition from nonsteroidal topical agents.
5. Formulary restrictions and pharmacy benefit manager control.

The most attractive growth opportunities are:

• A premium lotion with superior cosmetic properties;
• A scalp-compatible foam or solution;
• A metered spray for large or hair-bearing areas;
• A combination of anti-inflammatory treatment and barrier support;
• Authorized generic supply agreements;
• Regional licensing in markets with limited branded competition;
• Contract manufacturing of topical semisolids for dermatology companies.

A differentiated vehicle should demonstrate a measurable advantage in adherence, application time, patient preference, residue, or treatment-site coverage. A cosmetic claim without comparative evidence is unlikely to support durable premium pricing.

What geographic markets offer the best opportunity?

The United States offers the largest branded and generic infrastructure but has the highest competition and strongest payer pressure. Europe and Canada offer opportunities for topical corticosteroid manufacturers with established regulatory and distribution capabilities, although naming, potency classification, and reimbursement rules vary by country.

Emerging markets may offer lower development barriers for standard halobetasol products but present greater risks involving:

• Local patent clearance;
• Trademark ownership;
• Regulatory recognition of reference products;
• Quality-system enforcement;
• Counterfeit supply;
• Distributor concentration;
• Price controls.

A regional strategy should separate standard generic supply from premium formulation licensing. The same vehicle may command a premium in private dermatology markets but be treated as interchangeable in government procurement.

What patent litigation affects Ultravate?

For commercial diligence, the relevant litigation questions are:

• Whether an applicant has filed a Paragraph IV certification;
• Whether the NDA holder or patent owner filed suit within the statutory 45-day period;
• Whether FDA approval was subject to a 30-month stay;
• Whether the dispute ended through a judgment, dismissal, or settlement;
• Whether a settlement included a licensed entry date;
• Whether the case involved the active ingredient, formulation, method of use, or manufacturing process.

A settlement can materially delay generic entry even when a listed patent is later challenged. Litigation review should include district court dockets, Federal Circuit decisions, FDA patent records, and settlement disclosures. [4, 6]

Key Takeaways

• Ultravate is a halobetasol propionate 0.05% topical corticosteroid product with cream, ointment, and lotion vehicles.
• The active ingredient has limited new-product exclusivity value; commercial differentiation must come from formulation, packaging, distribution, or combination therapy.
• The highest-value excipient opportunities involve low-grease lotions, foams, sprays, airless pumps, and barrier-supportive vehicles.
• Conventional cream and ointment products face substantial generic-entry and price-erosion risk.
• Formulation patents are strongest when tied to defined composition ranges, microstructure, release performance, stability, or clinical advantages.
• A differentiated halobetasol product may support a 505(b)(2) strategy, but the regulatory and patent burden will be higher than for a standard ANDA.
• Manufacturing control over drug dispersion, viscosity, microbial quality, emulsion structure, and packaging compatibility is central to product equivalence.
• The most defensible commercial strategy is a premium, patient-preferred vehicle supported by comparative performance data.

Frequently Asked Questions

Can a new excipient create market exclusivity for Ultravate?

A new excipient alone rarely creates durable exclusivity. Protection is stronger when the excipient produces a defined technical or clinical result and the claims cover a specific composition, performance profile, or treatment method.

Is a halobetasol foam commercially attractive?

Yes. A foam can improve spreadability, drying time, and use on hair-bearing areas. Its value depends on clinical differentiation, packaging safety, manufacturing scale, and the ability to avoid direct substitution by low-cost generic creams.

Can Ultravate be reformulated with ceramides?

Yes, but the reformulation must preserve halobetasol uniformity, stability, release, and local tolerability. Ceramides may support barrier positioning but can also complicate emulsion structure and manufacturing control.

Are topical halobetasol products eligible for automatic pharmacy substitution?

Substitution depends on FDA therapeutic-equivalence ratings, the specific reference product, dosage form, state law, and payer policy. A lotion, cream, ointment, or foam should not be assumed to be substitutable across dosage forms.

What is the best commercial route for a new halobetasol product?

A standard cream is usually the lowest-cost route but has the greatest generic competition. A differentiated lotion, foam, spray, or barrier-supportive product offers stronger commercial positioning, with higher development and regulatory requirements.

References

1. U.S. Food and Drug Administration. (2024). Ultravate lotion, 0.05%: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Ultravate lotion, 0.05%: Inactive ingredients and product labeling. FDA.

3. U.S. Food and Drug Administration. (2024). Ultravate cream and ointment: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2022). Product-specific guidance for industry: Halobetasol propionate topical products. FDA.

6. U.S. Food and Drug Administration. (2024). Paragraph IV drug product patent litigation and settlements. FDA.